Does routine anticoagulant treatment improve prognosis or reduce thrombosis in lung cancer patients?
Routine anticoagulation in lung cancer patients does not improve overall survival and increases bleeding risk, indicating that anticoagulation should be individualized rather than applied routinely.
Objective We conducted this meta-analysis to investigate the utility of anticoagulant treatment in lung cancer patients. Method We retrieved studies focused on thrombosis and lung cancer by searching electronic databases. We evaluated the impact of thrombosis on the prognosis of lung cancer patients, assessed the efficacy and effect of anticoagulation treatment in lung cancer patients, and investigated risk factors for thrombosis in lung cancer patients. Result Lung cancer patients with thrombosis have a significantly worse overall survival. Anticoagulant treatment did not improve the prognosis of lung cancer patients. Although anticoagulant treatment was associated with a reduced incidence of venous thromboembolism and pulmonary embolism, there was an increased risk of hemorrhage in this population. The risk factors for thrombosis in lung cancer patients are adenocarcinoma, advanced tumor stage, and high serum levels of d-dimer. Conclusion Anticoagulation treatment in lung cancer patients should be more individualized. Routine anticoagulant treatment is not recommended.
Zhang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: